Hémoptysie cataméniale sous traitement hormonal substitutif

Chahine, Bachar; Malbranque, G.; Lelong, J.; Ramon, P.; Tillie‐Leblond, I.

doi:10.1016/s0761-8425(07)91066-9

Cited by 6 publications

(7 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Six patients had a history of ‘extensive’ or ‘severe’ endometriosis ( Manyonda et al , 1989 ; Joseph et al , 1994 ; Taylor et al , 1999 ; Badawy et al , 2004 ). Fourteen patients underwent surgical menopause years before presentation ( Skor et al , 1977 ; Stewart and Ireland, 1977 ; Kapadia et al , 1984 ; Ray et al , 1985 ; Manyonda et al , 1989 ; Joseph et al , 1994 ; Taylor et al , 1999 , 2005 ; Badawy et al , 2004 ; Giarenis et al , 2009 ), while only two transitioned naturally to menopause ( Goh and Hall, 1992 ; Chahine et al , 2007 ). One patient entered menopause as a result of premature ovarian insufficiency ( Mattar et al , 2008 ).…”

Section: Resultsmentioning

confidence: 99%

“…Unopposed oestrogen was implicated in numerous cases of symptom recurrence ( n = 12) ( Skor et al , 1977 ; Stewart and Ireland, 1977 ; Kapadia et al , 1984 ; Ray et al , 1985 ; Manyonda et al , 1989 ; Taylor et al , 1999 , 2005 ; Badawy et al , 2004 ; Giarenis et al , 2009 ). Fewer studies reported recurrence in women who were using combined hormonal preparations (oestrogen and progestagen) ( n = 5) ( Goh and Hall, 1992 ; Joseph et al , 1994 ; Badawy et al , 2004 ; Chahine et al , 2007 ; Mattar et al , 2008 ). In terms of method of oestrogen administration, oral tablets ( n = 5) ( Skor et al , 1977 ; Stewart and Ireland, 1977 ; Kapadia et al , 1984 ; Ray et al , 1985 ; Goh and Hall, 1992 ), implants ( n = 6) ( Manyonda et al , 1989 ; Taylor et al , 1999 , 2005 ) and patches ( n = 3) ( Badawy et al , 2004 ; Taylor et al , 2005 ) were all reported.…”

Section: Resultsmentioning

confidence: 99%

“…Oestrogen patch 0.05 mg weekly followed by various regimens of oestrogen and progestogen ( Badawy et al, 2004 ) 17. Oestradiol and cyproterone ( Chahine et al , 2007 ) …”

Section: Resultsmentioning

confidence: 99%

“…abdomen ( Taylor et al , 1999 ), iliac fossae ( Manyonda et al , 1989 ; Goh and Hall, 1992 ), genitals ( Taylor et al , 1999 ); and in more unusual sites such as the loin ( Manyonda et al , 1989 ). Abnormal bleeding was also a common presentation ( n = 14), including postmenopausal vaginal bleeding ( Taylor et al , 1999 ; Badawy et al , 2004 ; Giarenis et al , 2009 ), haematuria ( Skor et al , 1977 ; Stewart and Ireland, 1977 ; Kapadia et al , 1984 ; Ray et al , 1985 ; Taylor et al , 2005 ), rectal bleeding ( Taylor et al , 2005 ) and also haemoptysis ( Joseph et al , 1994 ; Chahine et al , 2007 ). Two women were reported to have pelvic masses ( Skor et al , 1977 ; Mattar et al , 2008 ).…”

Section: Resultsmentioning

confidence: 99%

“…bladder ( Skor et al , 1977 ; Stewart and Ireland, 1977 ; Taylor et al , 2005 ), ureter ( Kapadia et al , 1984 ; Ray et al , 1985 ; Manyonda et al , 1989 ; Taylor et al , 1999 ; Giarenis et al , 2009 ), ovary ( Goh and Hall, 1992 ), cervix ( Badawy et al , 2004 ), vagina ( Taylor et al , 1999 ; Giarenis et al , 2009 ); gastrointestinal organs ( n = 4), i.e. the bowel ( Stewart and Ireland, 1977 ; Taylor et al , 2005 ; Mattar et al , 2008 ) and rectum ( Giarenis et al , 2009 ); and the pulmonary system ( n = 2) including the lung ( Joseph et al , 1994 ) and bronchus ( Chahine et al , 2007 ). Mattar et al (2008) reported an unusual presentation involving an ovarian endometriotic cyst adherent to the small bowel with a solitary vascular pedicle ( Mattar et al , 2008 ).…”

Section: Resultsmentioning

confidence: 99%

See 4 more Smart Citations

The management of menopause in women with a history of endometriosis: a systematic review

Gemmell

Webster

Kirtley

et al. 2017

Human Reproduction Update

105

View full text Add to dashboard Cite

BACKGROUNDEndometriosis is typically regarded as a premenopausal disease, resolving after natural or iatrogenic menopause due to declining oestrogen levels. Nonetheless, case reports over the years have highlighted the incidence of recurrent postmenopausal endometriosis. It is now clear that both recurrence and malignant transformation of endometriotic foci can occur in the postmenopausal period. Postmenopausal women are commonly treated with hormone replacement therapy (HRT) to treat climacteric symptoms and prevent bone loss; however, HRT may reactivate endometriosis and stimulate malignant transformation in women with a history of endometriosis. Given the uncertain risks of initiating HRT, it is difficult to determine the best menopausal management for this group of women.OBJECTIVE AND RATIONALThe aim of this study was to systematically review the existing literature on management of menopausal symptoms in women with a history of endometriosis. We also aimed to evaluate the published literature on the risks associated with HRT in these women, and details regarding optimal formulations and timing (i.e. initiation and duration) of HRT.SEARCH METHODSFour electronic databases (MEDLINE via OVID, Embase via OVID, PsycINFO via OVID and CINAHL via EbscoHost) were searched from database inception until June 2016, using a combination of relevant controlled vocabulary terms and free-text terms related to ‘menopause’ and ‘endometriosis’. Inclusion criteria were: menopausal women with a history of endometriosis and menopausal treatment including HRT or other preparations. Case reports/series, observational studies and clinical trials were included. Narrative review articles, organizational guidelines and conference abstracts were excluded, as were studies that did not report on any form of menopausal management. Articles were assessed for risk of bias and quality using GRADE criteria.OUTCOMESWe present a synthesis of the existing case reports of endometriosis recurrence or malignant transformation in women undergoing treatment for menopausal symptoms. We highlight common presenting symptoms, potential risk factors and outcomes amongst the studies. Sparse high-quality evidence was identified, with few observational studies and only two randomized controlled trials. Given this paucity of data, no definitive conclusions can be drawn concerning risk.WIDER IMPLICATIONSDue to the lack of high-quality studies, it remains unclear how to advise women with a history of endometriosis regarding the management of menopausal symptoms. The absolute risk of disease recurrence and malignant transformation cannot be quantified, and the impact of HRT use on these outcomes is not known. Multicentre randomized trials or large observational studies are urgently needed to inform clinicians and patients alike.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

“…Oestrogen patch 0.05 mg weekly followed by various regimens of oestrogen and progestogen ( Badawy et al, 2004 ) 17. Oestradiol and cyproterone ( Chahine et al , 2007 ) …”

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

The management of menopause in women with a history of endometriosis: a systematic review

Gemmell

Webster

Kirtley

et al. 2017

Human Reproduction Update

105

View full text Add to dashboard Cite

show abstract

Current awareness: Pharmacoepidemiology and drug safety

2007

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 20 sections: 1 Reviews; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

show abstract

Hormonal replacements

2007

React. Wkly.

View full text Add to dashboard Cite

Hémoptysie cataméniale sous traitement hormonal substitutif

Cited by 6 publications

References 8 publications

The management of menopause in women with a history of endometriosis: a systematic review

The management of menopause in women with a history of endometriosis: a systematic review

Current awareness: Pharmacoepidemiology and drug safety

Hormonal replacements

Contact Info

Product

Resources

About